Atay Oguzhan sold $1.7M of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at $137.37 ($1.72M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Aug 6, 2026, 12:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the CEO/Chairman, including trade date, price, and post-transaction holdings, under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, primary-source datapoint on insider activity, but it is not a fundamental catalyst like earnings, guidance, or a deal.

03

What to watch

Traders may overreact to insider sales; the key differentiator here is the pre-arranged nature of the trades, which often reduces informational content.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-05 for a sale executed 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne (BLLN) disclosed a Form 4 showing CEO/Chairman Atay Oguzhan sold 12,500 shares at $137.37 on a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a primary-source Form 4 and includes transaction size and pricing, but it explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight versus unscheduled sales.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Atay Oguzhan

    Chairman and CEO who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.